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ABSTRACT Psoriasis has been linked to several comorbidities, including metabolic 
syndrome, atopy, and celiac disease. However, the association between immune 
thrombocytopenia and psoriasis has rarely been described. We report the case of an 
adolescent with severe psoriasis and concomitant immune thrombocytopenia who 
obtained remission during treatment with adalimumab. Increased concentration of 
tumor necrosis factor-α seems to be a pathogenic linkage and therapeutic target for 
both diseases.
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INTRODUCTION
Psoriasis is a chronic inflammatory disease that 
affects about 2% of the population worldwide. The 
pediatric subset of the psoriasis population is an im-
portant subgroup since nearly one third of patients 
with psoriasis experience disease onset in childhood 
(1,2). The affected children and adolescents face a 
combination of physical and psychosocial challeng-
es. Pediatric psoriasis is associated with pronounced 
effects on self-esteem, stigmatization, and social rela-
tionships compared with their disease-free peers (3). 
Recent research has linked psoriasis to several comor-
bidities, including metabolic syndrome, atopy, celiac 
disease, vitiligo, and alopecia areata (4).
Immune thrombocytopenia is one of the most 
common acquired bleeding disorders in children sec-
ondary to the production of autoantibodies against 
platelets (5). The association of immune thrombocy-
topenia and psoriasis has rarely been described (6,7). 
CASE PRESENTATION
We present a case of 16-year-old girl with an 8-
year history of plaque psoriasis. Over the course of 
disease, the patient was treated with topical agents, 
narrow band UVB phototherapy (3 sessions/week for 
4 months), acitretin (0.5 mg/kg bw/day for 5 months), 
methotrexate (20 mg/week for 7 months), and cyclo-
sporine (3.5 mg/kg bw/day for 6 months); however, 
no clinically meaningful response was observed. The 
patient was also diagnosed with immune thrombo-
cytopenia at the age of 12.
On admission to our Department, physical ex-
amination revealed extensive erythematous scaly 
plaques involving 48% of the body surface area 
(BSA) (Figure 1). The psoriasis area severity index 
(PASI) score was assessed as 34.9. Psoriasis had a pro-
found negative impact on the patient’s quality of life 
(Children’s Dermatology Life Quality Index – CDLQI 
– 27 points). 
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Total blood count test revealed isolated throm-
bocytopenia (82×103/dL). Kidney and liver function 
tests, fasting blood glucose, and lipid profile showed 
no abnormalities. Serological markers for hepatitis B 
and C, human immunodeficiency virus, and interfer-
on-γ release assay were negative.
Because of the severity of the disease and lack of 
response to standard systemic therapies, the patient 
received 40 mg adalimumab subcutaneously every 2 
weeks. A rapid improvement was observed after the 
first two injections, with almost complete remission 
in the following weeks (outcomes at week 12: PASI – 
2.4; BSA – 4%; CDLQI – 3; Figure 2). No adverse events 
were observed during biologic therapy. The platelet 
count increased moderately to 121×103/dL.
DISCUSSION
Although pediatric psoriasis generally has a mild 
clinical course, a certain group of patients is refractory 
to conventional systemic agents. Biological treatment 
targeting specific immune components in the patho-
physiological cascade of psoriasis is becoming a prom-
ising therapeutic alternative (2,8). We described the 
case of a 16-year-old girl with severe psoriasis poorly 
controlled by conventional treatments and concomi-
tant immune thrombocytopenia.
Immune thrombocytopenia is a benign condition 
and one of the common causes of thrombocytopenia 
in adults and children that resolves spontaneously. 
However, 20-30% of patients develop the chronic form 
that requires more intensive treatment including corti-
costeroids, intravenous immunoglobulin, rituximab, or 
splenectomy (9). Due to potential platelet-lowering ef-
fect of immunosuppressive drugs, systemic treatment 
of pediatric psoriasis concomitant with immune throm-
bocytopenia poses a substantial clinical challenge. 
Our patient demonstrated a good clinical response 
to adalimumab, which has been approved in 2015 by 
the European Medicines Agency for the treatment of 
severe plaque psoriasis in children aged 4 years or old-
er. Adalimumab is a fully human monoclonal antibody 
against tumor necrosis factor α (TNFα), a key cytokine 
in a number of autoimmune diseases (10). 
Increased blood concentration of TNFα has been 
reported in patients with immune thrombocytopenia 
(11). Additionally, single-nucleotide polymorphism in 
the TNFα gene (308G/A) was reported to affect gene 
transcription by increasing TNFα production and was 
speculated to increase the risk and exacerbate the out-
come of ITP (12). 
We decided to use adalimumab in our patient due 
to inadequate response to conventional treatment, 
relatively short half-life of the drug (in case of adverse 
events), and the possibility of continuing the therapy 
with health care reimbursement after reaching adult-
hood. Monocytes and macrophages are considered 
to be the main producers of soluble TNFα, although 
activated CD4 T-cells highly express transmembrane 
TNFα which provides a co-stimulatory signal for hu-
man B-cell activation, a remarkable feature of ITP (13). 
The possibility of neutralizing the soluble and mem-
brane-bound TNFα was an additional argument for 
starting therapy with adalimumab for both diseases.
Figure 1. Diffuse erythematous scaly plaques before treat-
ment with adalimumab.
Figure 2. Clinical improvement after 12 weeks of therapy 
with adalimumab.
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On the other hand, the literature provides very 
few reports of thrombocytopenia in patients with 
psoriasis who were treated with biologics such as 
etanercept, adalimumab, infliximab, ustekinumab, or 
secukinumab (14-16). The exact mechanism by which 
biological drugs may induce thrombocytopenia in 
psoriasis remains unclear. This reaction may be due 
to the relative excess of Th2 lymphocytes, which may 
in turn stimulate antiplatelet antibody production, 
leading to platelet destruction and thrombocytope-
nia. Another explanation is that biologics are associ-
ated with formation of immune complexes, which 
in turn bind to the surface of platelets and activate 
the complement cascade. Some authors suggest that 
thrombocytopenia is an idiosyncratic reaction in ge-
netically predisposed patients (17).
It is important for clinicians to be aware of this side 
effect of biological drugs. However, the potential risk 
of drug-induced thrombocytopenia does not repre-
sent a contraindication for the administration of bio-
logics in psoriasis. Instead, as illustrated by this case, 
it may be applied as an attractive treatment for both 
psoriasis and immune thrombocytopenia. Since all 
agents pose a substantial risk, platelet counts should 
be regularly monitored in patients receiving anti-
TNFα/IL-23/IL-17 biologics to facilitate early recogni-
tion of thrombocytopenia.
CONClUSION 
Psoriasis and immune thrombocytopenia are 
quite common in the pediatric population, but their 
coexistence is rare. We would like to emphasize that 
altered TNFα expression may be a pathogenic linkage 
and therapeutic target for both diseases. 
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